PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY STUDY THAT WILL ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND HEMODYNAMIC RESPONSE TO A SINGLE 30 MINUTE INTRAVENOUS INFUSION OF VASOMERA™ (PB1046) IN ADULT SUBJECTS WITH STAGE 1 OR 2 ESSENTIAL HYPERTENSION: